SMMNY Overview

Siemens Healthineers Spinoff: Siemens is planning to offload a significant portion of its Siemens Healthineers business through a direct spinoff, a rare move for a major German company, potentially reducing its ownership to below 40%.

Dividend in Kind: The spinoff will involve distributing a sizable stake in Healthineers to shareholders as a dividend in kind, with plans to be disclosed as early as next week.

Tax Implications: Early discussions with tax authorities suggest that the transaction is unlikely to impose a significant tax burden on investors, according to sources familiar with the matter.

Investor Day Announcement: Siemens is expected to outline its business strategy during its investor day on November 13, with several options still under consideration regarding the spinoff.

First Quarter Performance: Siemens Healthineers reported a strong first-quarter performance with revenues of €5.5 billion, exceeding analyst expectations by 2.1%, and earnings per share (EPS) at €0.42, which is 4.3% above forecasts.

Future Projections: Analysts maintain a consensus forecast for 2025 revenues at €23.8 billion, reflecting a modest growth rate, while the price target remains stable at €61.60, indicating no significant change in sentiment regarding the company's long-term performance.

Coloplast and Elekta Ratings Update: Bernstein analysts upgraded Coloplast to "outperform" due to expected growth from easing cost inflation, while Elekta was raised to "market-perform" as consensus estimates now reflect its operational challenges.

Philips Remains Top Pick: Despite recent struggles, Philips is still favored by Bernstein, with projections of a 14% CAGR in earnings per share over the next five years, supported by recovery in other segments and margin improvements.

UBS Downgrade: Siemens Healthineers AG has been downgraded by UBS from a "buy" to a "neutral" rating due to concerns over its medium-term growth prospects, particularly in the Chinese market where competition from local firms is increasing.

Financial Forecast Revision: UBS has revised its financial forecasts for Siemens Healthineers, expecting group revenues to decline by 1% to 3% from 2025 to 2028, and has lowered its price target to €51, reflecting the anticipated impact of competitive pressures and a reduced growth outlook.

Siemens Healthineers Acquisition: Siemens Healthineers is set to acquire Novartis' Advanced Accelerator Applications (AAA) diagnostic arm for over €200M, aiming to enhance its PET radiopharma business in Europe by bringing radioactive compound manufacturing closer to patients.

Transaction Timeline and Background: The deal, which follows Novartis' $3.9B acquisition of a French cancer specialist, is expected to close in Q4 2024, pending regulatory reviews and discussions with Novartis’ works council.

Analyst Upgrade: BNP PARIBAS EXANE has upgraded Siemens Healthineers AG's outlook from Neutral to Outperform, with a projected one-year price target of $32.74/share, indicating an 11.02% upside from its current price of $29.49/share.

Institutional Investment Increase: There has been a significant increase in institutional ownership of Siemens Healthineers AG, with a 44.44% rise in the number of funds reporting positions and a 70.59% increase in total shares owned over the last three months.